RNS Number : 3482M

Societe Generale SA

08 May 2020

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1)	Société Générale S.A.
Company dealt in	Allergan plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	US$0.0001 ordinary shares
Date of dealing	07/05/2020

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	1,956,581	0.59	70,877	0.02
(2) Derivatives (other than options)	0	0.00	1,771,191	0.54
(3) Options and agreements to purchase/sell	58,500	0.02	0	0.00
Total	*6,461,041	*1.96	1,842,068	0.56

* Include the holding of 4,445,960 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit USD (Note 5)
Purchase	100	193.23
Purchase	100	194.45
Purchase	100	193.63
Purchase	100	193.22
Purchase	100	192.67
Purchase	100	192.94
Purchase	100	194.4
Purchase	100	194.22
Purchase	100	193.79
Purchase	100	193.34
Purchase	100	194.55
Purchase	100	194.21
Purchase	100	193.45
Purchase	400	194.75
Purchase	100	194.67
Purchase	100	194.22
Purchase	100	193.07
Purchase	100	194.26
Purchase	100	194.4
Purchase	100	194.55
Purchase	100	193.88
Purchase	100	193.06
Purchase	100	194.29
Purchase	100	193.18
Purchase	100	194.38
Purchase	100	194.24
Purchase	88	194.75
Purchase	100	193.51
Purchase	12	194.75
Purchase	100	194.32
Purchase	97	194.6
Purchase	3	194.6
Purchase	100	193.27
Purchase	100	194.55
Purchase	100	194.15
Purchase	200	193.63
Purchase	5	192.93
Purchase	95	192.93
Purchase	200	194.65
Purchase	100	194.65
Purchase	100	194.4
Purchase	100	194.09
Purchase	100	193.79
Purchase	100	194.52
Purchase	100	194.55
Purchase	100	194.56
Purchase	96	193.89
Purchase	100	194.58
Purchase	96	193.6
Purchase	4	193.6
Purchase	100	193.14
Purchase	100	193.22
Purchase	200	192.99
Purchase	100	194.21
Purchase	200	194.67
Purchase	100	194.64
Purchase	100	192.94
Purchase	100	194.25
Purchase	100	194.43
Purchase	100	193.72
Purchase	100	194.32
Purchase	100	193.51
Purchase	100	194.79
Purchase	54	193.00889
Purchase	700	192.99
Purchase	100	193.86
Purchase	12	193.16
Purchase	101	192.99
Purchase	4,645	192.99
Purchase	5	192.99
Purchase	132	192.99
Purchase	100	194.79
Purchase	2,045	192.98655
Purchase	100	194.8
Sale	72	194.62
Sale	100	194.71
Sale	14	194.59
Sale	100	194.03
Sale	11	194.33
Sale	45	195.02
Sale	26	194.85308
Sale	24	194.56
Sale	786,600	192.99
Sale	100	194.53
Sale	100	194.73
Sale	76	194.56
Sale	11	194.53
Sale	200	195.03
Sale	3	193.168
Sale	2,000	193.9006
Total Purchases	14,590
Total Sales	789,482

(b)      Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit USD (Note 5)
Equity Linked Swap	Expiry	150,000	N/A
Equity Linked Swap	Decreased short	576,600	192.99

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name, e.g. call option Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name, e.g. call option Number of securities Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8) Details Price per unit (if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            Yes

Date of disclosure	08/05/2020
Contact name	Société Générale - Disclosure team
Telephone number	+33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap23

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL 

ACT, 1997, TAKEOVER RULES, 2013

DETAILS OF OPEN POSITIONS

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

OPEN POSITIONS (Note 1)

Product name, e.g. call option	Written, or purchased	Number of relevant securities to which the option or derivative relates	Exercise price (Note 2)	Type, e.g. American, European etc.	Expiry date
Listed Put Option	Sale	40,000	175	American options	15/01/2021
Listed Put Option	Sale	18,500	190	American options	15/01/2021

Notes

1.          Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

2.          For all prices and other monetary amounts, the currency must be stated.

For full details of disclosure requirements, see Rule 8 of the 

Rules. If in doubt, consult the Panel.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ISEKKFBNOBKKAPK